Merck & Co., Inc. (MRK) No Longer Has Breakthrough Therapy Status For Its Hepatitis C Drug

February 4, 2015 9:30 PM

13 0

Merck announced that the FDA has withdrawn its breakthrough therapy designation for the company’s hepatitis C treatment drug

Merck & Co., Inc. (NYSE:MRK) announced Wednesday that the US Food and Drug Administration (FDA) has issued a notice detailing plans to rescind its Breakthrough Therapy Designation for the company's hepatitis C treatment drug.

Read more

To category page